Clinical Trial Update: Low Dose Versus High Dose Methylene Blue in Septic Patients [Phase 2, Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 2/3 trial comparing low-dose versus high-dose methylene blue in patients with septic shock.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• METHYLENE BLUE (METHYLENE BLUE)

Snippet

Sponsor: National Cancer Institute, Egypt | Conditions: Septic Shock | Phase 2, Phase 3 | Status: COMPLETED